MedTrace Logo

Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme

NCT02120287 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-05-07

Study results available
· View outcomes & findings →

Summary

This is a phase II study on the usage of stereotactic Gamma Knife radiosurgery as a boost to the tumor bed border zone in conjunction with the usage of bevacizumab.

Conditions

Interventions

DRUG

Bevacizumab

Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.

PROCEDURE

Magnetic Resonance Spectroscopy (MRS)

Subjects will have MRS prior to BZ-SRS.

PROCEDURE

Border Zone Stereotactic Radiosurgery (BZ-SRS)

The 'border zone' of the tumor will be targeted by SRS in a single session.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Ajay Niranjan

    lead OTHER

Principal Investigators

  • Ajay Niranjan, MD · University of Pittsburgh Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-03-31
Completion
2018-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02120287 on ClinicalTrials.gov